The U.S. Patent and Trademark Office’s (USPTO) Appeals Review Panel has offered crucial guidance on the utilization of means-plus-function claims in relation to antibody patents. This development comes as the panel affirmed the rejection of claims concerning a Xencor Inc. patent application, which is said to pertain to treating autoimmune diseases.
The means-plus-function claiming technique is a notably unique component of the U.S patent law. Its core purpose is to describe a claim element by the operation it performs instead of its specific structure. This has often been lauded for providing inventors and patent owners an arguably broader claim scope and better infringement detection, underlining its importance in practical patent usage. That the Appeals Review Panel would provide clarity in its application to antibodies is therefore of significant interest.
At the same time, the continued repudiation of Xencor Inc.’s patent application may reveal an equally striking perspective on the office’s view concerning antibody patents and their basis for autoimmune treatment. However, as not all specifics regarding this application or its rejection have been made public, certain assessments cannot be fully elucidated.
For more detailed on-site coverage, including the patents review panel’s reasoning, commentary from legal experts, and the potential implications for future antibody patenting, please refer to the original article.